NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

Core Viewpoint - NurExone Biologic Inc. has established Exo-Top Inc. as a strategic U.S. subsidiary to enhance its manufacturing, clinical advancement, and long-term value creation in the biotechnology sector focused on exosome-based therapies [1][2]. Group 1: Exo-Top Sublicense Agreement - NurExone Ltd. has granted Exo-Top certain rights under an exclusive worldwide development and commercialization license with Technion Research and Development Foundation Ltd. and Ramot, which is aimed at supporting future manufacturing and commercial activities for naïve exosomes in the U.S. [1][2] - The Exo-Top Sublicense is expected to enhance strategic flexibility in the U.S. market, aligning with NurExone's long-term strategy [2][3]. Group 2: Strategic Importance of Exo-Top - Exo-Top is positioned as a key component of NurExone's North American strategy, focusing on manufacturing, development, and commercialization of exosome-based therapeutics [4][5]. - One of Exo-Top's critical assets is its Master Cell Bank, which ensures batch-to-batch consistency essential for clinical translation and commercial readiness [4]. Group 3: Financial Obligations and Expectations - Under the Tech License, NurExone is obligated to pay certain royalty fees upon reaching Phase II of clinical trials and additional royalties upon commercialization, but no monetary consideration was paid by Exo-Top to NurExone Ltd. for the sublicense [3][5]. - The company does not anticipate any sublicense fees to be payable to TRDF in connection with the Exo-Top Sublicense execution [3].